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ABSTRACT
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition dur-
ing pregnancy. Explanation of the GDM pathogenesis is important due to preventing gestational complications. During 
pregnancy there are significant changes in maternal metabolism. Many of these changes are influenced by different adi-
pokines produced in the placenta and adipose tissue. The exact role of adipokines in the pathogenesis of GDM remains 
still unknown. Several adipokines have been analysed throughout gestation and their levels have been suggested as 
biomarkers of maternal–perinatal outcomes. Some of them have been postulated as significant in the pathogenesis of 
pregnancy complications like GDM.
This report aims to review some of the recent topics of adipokine research that may be of particular importance in patho-
physiology and diagnosis of gestational diabetes mellitus. Because of manuscript length limitations, after thorough literature 
review and in view of the recent evidence, we focus on the one of the most well-known adipokine: adiponectin, and not 
so well-studied: nesfatin-1, chemerin, ghrelin, and CTRP 1. 
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INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as any 
degree of glucose intolerance with onset or first detected 
during pregnancy. It is the most common metabolic disorder 
of pregnant women. The frequency of GDM may range from 
5 to 20% of all pregnancies, depending on the population 
studied and the diagnostic tests employed. GDM represents 
one of the major problems in perinatal medicine because 
women with GDM have an increased risk for prenatal mor-
bidity and significantly elevated risk for type 2 diabetes 
mellitus (T2DM) in later life [1].
Explanation of the GDM pathogenesis is important 
due to the possibility of preventing gestational compli-
cations. The underlying pathophysiological mechanism of 
GDM is believed to be the composition of decreased insulin 
sensitivity of the mother before pregnancy and insufficient 
insulin response during pregnancy. Pregnancy is associated 
with progressive insulin resistance. During each trimester 
there are some physiological mechanisms that increase 
food intake, promotes the adipogenesis and energy stora-
ge for the high metabolic requirements of pregnancy and 
lactation. Many of these maternal metabolic changes during 
gestation are influenced by different adipokines produced in 
the placenta and adipose tissue. It has been observed that 
adipokines cause insulin resistance in normal pregnancy 
but the exact role of adipokines in the pathogenesis of 
GDM remains unknown. Several adipocytokines have been 
analysed throughout gestation and their levels have been 
postulated as biomarkers of maternal–perinatal outcomes, 
some of them with pathophysiological significance [2].
This report aims to review the recent topics of adipokine 
research: adiponectin, nesfatin-1, chemerin, ghrelin and 
complement C1q tumor necrosis factor related proteins 
1 (CTRP 1) that might be of particular importance in patho-
physiology and diagnosis of gestational diabetes mellitus. 
Because of manuscript length limitations, after thorough 
literature review and in view of the recent evidence, we focus 
on the one of the most well-known adipokine: adiponectin, 
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and not so well-studied: nesfatin-1, chemerin, ghrelin, and 
CTRP 1. Also, in our laboratory and clinical studies we will 
analyse the concentration of this adipokines and we will 
try to find the correlation between this adipokines levels 
and possible clinical application of this measurements in 
prediction of GDM. 
ADIPONECTIN
Adiponectin is a 244-amino-acid-long polypeptide hor-
mone representing adipokines family which modulates 
different biological processes. Adiponectin is known to be 
produced not only by adipose tissue but also within the 
intrauterine environment and stimulates the glucose up-
take in skeletal muscles and decreases the hepatic glucose 
synthesis [3].
Levels of the adiponectin are inversely correlated with 
body fat percentage, fasting glucose and insulin concen-
tration, and insulin resistance in adults. It is believed that 
circulating adiponectin levels are increased during caloric 
restriction. The adiponectin concentration is decreased in 
obese and/or type 2 diabetic patients. The inverse correla-
tion between the adiponectinemia and abdominal obesity, 
and the strong positive correlation between the adiponectin 
levels and the insulin sensitivity has been described [4]. It has 
been proved that the adiponectin expression is inhibited by 
pro-inflammatory cytokines, hypoxia, oxidative stress and all 
of them are typically observed in obese patient. Adiponectin 
can reduce ectopic fat storage by stimulating lipid oxida-
tion and decreasing adipose tissue lipolysis. Intravenous 
injection of recombinant adiponectin in rodent models of 
insulin resistance improved normal insulin sensitivity [5]. 
The study of Mazaki-Tovi et al. has revealed that the 
adiponectin levels during 1st, 2nd and 3rd trimester were 
comparable and were significantly higher than in puerpe-
rium. Authors noticed that despite the increasing insulin 
resistance as pregnancy progresses, there were no signifi-
cant changes in the adiponectin levels. This may signify that 
the regulation of the adiponectin release during gestation 
is altered. The elevated gestational adiponectin levels could 
be in accordance with the postulated increased “adiponectin 
resistance” during pregnancy [6]. It has not been confir-
med whether the placenta is the source of adiponectin [3, 
6]. Low maternal adiponectin levels and decreased insulin 
sensitivity may facilitate the glucose transport to the fetal 
circulation and be responsible for macrosomia. Adiponectin 
can be detected in fetal circulation after 24th week and the 
level tends to increase as pregnancy progresses. The fetal 
adiponectin levels have been found to be significantly hi-
gher than those in the mother [7]. 
Adiponectin is adipokine, which relation to GDM was 
the most widely studied but the results of research are not 
unambiguous. It has been published that adiponectin levels 
decrease in GDM patients when compared to healthy ones 
and there are also some studies indicating that the levels 
of adiponectin do not differ in GDM and normal pregnancy. 
Cortelazzi et al. have found that the circulating adiponectin 
levels were decreased in patients with GDM as compared 
to pregnant controls independent of pre-pregnancy body 
mass index (BMI) and the insulin sensitivity [8]. Bao et al. 
have showed in their meta-analysis that concentration of 
adiponectin was significantly lower in first and early second 
trimester in pregnant woman who later had diagnosed 
with GDM. This reduction of adiponectin levels may be 
correlated with the developing of GDM through decreased 
insulin sensitivity and anti-inflammatory capability. It has 
been published that the risk of GDM is 5-6 times higher 
in women with low adiponectin levels when compared to 
women with high levels [9]. An association between signifi-
cantly decreased concentration of adiponectin and beta cell 
dysfunction during pregnancy has been found what may 
suggest the use of adiponectin as an early predictor of the 
GDM development [10].
NESFATIN-1
Nesfatin-1 is a 82 amino acid peptide derived from the 
previously described protein nucleobindin-2 (NUCB2), that 
is encoded by the NUCB2 gene. Nesfatin-1 is secreted by 
peripheral organs and tissues (pancreas, duodenum, sto-
mach, adipose tissues) and nervous system. Nesfatin-1 has 
significant impact on carbohydrate metabolism by inhibi-
ting glucagon release and has a glucose-dependent insuli-
notropic effect. The level of nesfatin increases after feeding. 
Nesfatin-1 has been shown to regulate the hunger and 
satiety sensations, body weight and is expressed in seve-
ral regions of the hypothalamus playing the main role in 
controlling food intake [11]. Nesfatin-1 has a big impact on 
blood glucose levels and endogenous nesfatin-1 concentra-
tion is changed in diabetes. The significant reduction in the 
fasting plasma nesfatin-1 levels in T2DM and PCOS patients 
has also been noticed. It might be related to impaired insulin 
sensitivity and suggests that nesfatin-1 could be inhibited 
by hyperglycemia, hyperinsulinemia and insulin resistance 
[12]. There are only a few studies, which showed decre-
ased level of nestafin-1 in the pregnant woman with GDM 
[13, 14]. Kucukler et al. have observed that nesfatin-1 level 
was lower and insulin concentration was higher in GDM 
group than in control one. The negative correlation has 
been found between nesfatin-1 levels and weight, BMI, 
the glucose concentration fasting and at first hour level of 
the 50 g OGTT and with homeostasis model assessment 
of insulin resistance (HOMA-IR). The positive correlation 
between nesfatin-1 and insulin concentrations have been 
showed. These observations may be suggestive of a role 
of nesfatin-1 in the pathophysiology of GDM. Therefore, 
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when nesfatin-1 involvement in GDM pathogenesis is clear, 
its assessment may be useful as early biomarker of GDM 
development [14].
Aslan et al. have been revealed that nesfatin-1 levels 
were lower in patients with GDM compared with healthy 
ones. The cord blood nesfatin-1 levels were similar in the 
GDM and control groups and maternal serum nesfatin-1 le-
vels correlated strongly and positively with their respective 
cord blood concentrations [13]. Su et al. have been sugge-
sted that the reduction of nesfatin-1 level in serum of pre-
gnant patients and the decrease of its insulinotropic effect 
lead to dysregulation of insulin release in GDM patients [15]. 
In addition, they have also reported that the intravenous 
injection of nesfatin-1 suppresses hyperglycemia in ob/ob 
mice by increasing insulin action. Therefore, nesfatin-1 could 
act as anti-diabetic factor in pregnant women with GDM 
[15]. Another study has found the increased levels of nesfa-
tin-1 in fetuses of mothers with GDM. It was well established 
that these fetuses have been exposed to high glucose con-
centrations in utero. Thus, it may be hypothesized that the 
adverse hyperglycemic intrauterine environment in GDM 
patients could result in increased fetal nesfatin-1 levels in 
comparison to the control group. Nevertheless, in neonates 
of GDM mothers glucose dysregulation after birth was not 
observed, probably due to balancing mechanisms involving 
endogenous insulin secretion [12].
CHEMERIN
Chemerin, also known as retinoic acid receptor responder 
protein 2 (RARRES2),  is a 14 kDa protein secreted in an in-
active precursor as prochemerin and is activated through 
fragmentation of the C-terminus by inflammatory and co-
agulation serine proteases. Chemerin is a novel adipokine 
playing an essential role in adipocyte differentiation and 
insulin signalling. Chemerin and its receptor, chemokine-like 
receptor 1 (CMKLR1, or ChemR23) are higly expressed and se-
creted in various tissues, especially white adipose tissue, and 
they are thought to play an important role in inflammation 
and metabolic complications associated with obesity [16]. 
Chemerin levels are increased in obesity and it is connected 
with numerous components of the metabolic syndrome. 
The increased concentration of chemerin observed in obese 
patient is postulated to play an important role in the deve-
lopment of type 2 diabetes as an effect of dysregulation of 
the important physiological processes regulated by chemerin 
[16]. Fatima et al. have analysed the levels of adipokines (inclu-
ding chemerin) and their relations to the clinical phenotypes 
of GDM and the fetal growth parameters. Level of chemerin 
was seven folds higher in study group versus control one. The 
adipokines (chemerin, IL-18 and leptin) had positive correla-
tion with fasting blood glucose concentration, HOMA-IR, fetal 
weight, and negative correlation with quantitative insulin 
sensitivity check index (QUICKI). The higher chemerin levels 
were identified in 96% cases. In conclusion, authors have 
suggested that the high chemerin and leptin levels seen in 
GDM may play a role in the development of insulin resistance 
through a subclinical inflammation [17]. Li et al. have noticed 
that serum chemerin in obese normal glucose tolerant (NGT) 
group and normal-weight-GDM group was significantly hi-
gher than that of normal weight NGT group. There was no 
significant difference of CMKLR1 (encoding the receptor of 
chemerin) mRNA expression between normal weight NGT 
and normal weight GDM group [18].
Van Poppel and colleagues analysed concentration of 
chemerin in arterial and venous cord blood in infants of GDM 
and non-GDM patients, in their mothers at the beginning 
of the third trimester and at delivery and in amniotic fluid 
of GDM patients. In GDM group increased concentration 
of chemerin in fetal arterial cord blood were found but the 
difference in venous cord blood were not observed. Che-
merin level in venous cord blood was higher in infants of 
obese women. Arterial and venous levels were associated 
with maternal chemerin levels at birth, and also chemerin 
level in arterial blood was correlated with GDM status [19]. 
Pfau et al. have reported that maternal serum cheme-
rin concentrations were not significantly different in GDM 
patients as compared to control group. Chemerin level si-
gnificantly and positively was correlated with HOMA-IR and 
serum levels were highest in patients in the third tertile of 
HOMA-IR [20]. Ademoglu and colleagues have noticed that 
serum chemerin levels were significantly higher in subjects 
with GDM than in healthy pregnant controls. Fasting insulin 
concentration was similar in both groups. In multiple linear 
regression analyses, chemerin was significantly correlated 
with BMI, HbA1c, HDL-cholesterol, triglyceride, insulin levels 
and HOMA-IR [21]. 
The impact of maternal obesity and GDM on maternal 
chemerin concentrations has been analysed, and no effect 
was revealed. However, chemerin levels were significantly 
higher in cord plasma from obese women. There was no 
effect of GDM on maternal and cord chemerin concentra-
tions, and on the release of chemerin from placenta and 
adipose tissue [22]. 
Lehrke et al. have noticed the increased chemerin levels 
during third trimester of pregnancy. They suggested that it 
might be related to proinflammatory conditions due to high 
levels profile of mediators of inflammation such as TNF-alfa, 
resistin or IL-6 [23].
GHRELIN
Ghrelin is a 28-aa Ser3 acylated peptide called “hunger 
hormone” which regulates glucose homeostasis by altering 
insulin secretion and is also involved in the regulation of 
both glycogenolysis and gluconeogenesis. In animal studies, 
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the elimination of ghrelin improves the diabetic phenoty-
pe with significantly increased insulin secretion, improved 
glucose tolerance and decreased fasting glucose level [24]. 
Ghrelin is secreted from the gastrointestinal tract and plays 
an important role in the regulation of eating behaviour 
through appetite modulation and the regulation of body 
weight [25]. It has been suggested that ghrelin and obe-
statin are significant in GDM pathophysiology based on the 
comparing of their measurement after and before delivery 
[26]. The increased fasting serum ghrelin level in the 2nd 
trimester may be associated connected with weight gain 
during pregnancy [24]. 
Baykus et al. observed that serum ghrelin, obestatin and 
preptin levels were statistically higher in GDM and physio-
logical pregnancy in the puerperium when compared to 
the pregnancy period. The positive correlation was found 
between ghrelin and preptin, and preptin and insulin in the 
GDM group [26]. A negative regulatory feed-back mecha-
nism between resistin, TNF-alpha and ghrelin could be also 
postulated. It could be a risk factor for developing gestational 
diabetes mellitus. The decreased ghrelin concentration has 
been found in pregnant women compared to postpartum 
levels. In pregnant patients with type 1 diabetes and lactating 
mothers with GDM, serum ghrelin concentrations were found 
to be lower than those of the control group. Aydin et al. have 
also observed that mothers with GDM have a significant lower 
(more than two-fold) serum ghrelin level [27]. Another study 
has shown that ghrelin levels were lower in diabetic pregnant 
women, although pre-term birth appeared to reverse this 
trend in GDM group. The concentrations were lower in pre-
gnant women with diabetes and HbA1c of < 6.5%. It has been 
suggested that ghrelin is involved in the adaptation to the 
caloric imbalance in GDM patients and may play a similar role 
in pregnancy-related complications, since high ghrelin con-
centrations may be vital for normal fetal development [28]. 
Riedl et al. have observed that whereas basal ghre-
lin concentrations are suppressed during pregnancy, the 
downregulation of ghrelin by glucose uptake is markedly 
reduced [29]. They have suggested that this suppression is 
not caused by the reduced insulin sensitivity in pregnant 
patient. They found no correlation between plasma ghrelin 
and pregestational BMI or weight gain during pregnancy. 
In conclusion, authors have noticed that both in the fasting 
state and suppressed ghrelin plasma concentrations are si-
gnificantly lower during pregnancy, but fasting ghrelin level 
is not related to insulin sensitivity. Thus, the suppression of 
ghrelin throughout whole pregnancy appears to have other 
reason and/or purpose [29]. 
The decreased umbilical cord ghrelin levels have been 
observed in women with GDM. The negative correlation be-
tween cord blood ghrelin concentration and birth weight 
was also found [30]. It has been revealed that fasting plasma 
glucose during pregnancy and in puerperium, and post-
-partum C-peptide and ghrelin levels were significant risk 
factors for the development of type 2 diabetes in women with 
previous GDM. Lappas et al. have suggested that C-peptide 
and ghrelin might be potential biomarkers in the prediction 
of type 2 diabetes in patient with a history of GDM [31].
CTRP 1
Complement C1q tumor necrosis factor related proteins 
(CTRPs) is the family of proteins characterized by a common 
TNF alpha–like globular domain. Currently, 15 members are 
identified [32]. CTRP 1 is a member of the CTRPs group com-
prising family characteristic collagen and TNF-like domains 
and exhibit marked expression in vessel wall. The structural 
homology of CTRP1 and adiponectin has been described, 
but expression of CTRP1 is unlike adiponectin. CTRP 1 is 
mainly expressed in adipose tissue and derived mostly from 
stromal vascular cells composed of adipose-tissue macro-
phages, preadipocytes and endothelial cells. Its expression 
is markedly higher in fatty tissue of db/db mice and Zucker 
diabetic fatty (fa/fa) rats [33]. 
It is believed that abnormal synthesis and secretion 
of CTRP 1 change glucose metabolism by causing insulin 
resistance in adipose tissue, liver and skeletal muscles. Spe-
cific CTRP 1 receptor has not been yet described but animal 
studies showed that the injection of CTRP 1 was sufficient 
to decrease blood glucose levels and increase energy input 
required by activating protein kinase (AMPK) signalling 
cascade in the skeletal muscles [32]. 
Although several animal experiments have postulated 
CTRP1 as an important regulator of glucose metabolism and 
insulin sensitivity, the clinical observations in humans are still 
poorly characterized [34]. Recent studies have indicated that 
the circulating levels of CTRP 1 were significantly increased in 
subjects with metabolic syndrome [35]. It has been revealed 
that serum CTRP 1 concentrations were markedly higher in 
subjects with T2DM comparing to the healthy subjects and 
serum CTRP 1 levels were correlated with the insulin secre-
tion and sensitivity in this both groups. Thus, the elevation 
of serum CTRP 1 levels in T2DM patients may reflect a self-
-protective mechanism in response to the incorrect glucose 
metabolism [34]. Serum CTRP 1 concentrations in healthy 
subjects were also associated with fasting insulin levels and 
basal insulin secretion (HOMA-%B), suggesting that serum 
CTRP 1 levels are dependent on insulin secretion in healthy 
human subjects [35]. Xin et al. showed that circulating CTRP 
1 levels are elevated in T2DM patient and independently 
correlated with T2DM risk factors including BMI, fasting blo-
od glucose levels, HbA1c, LDL cholesterol, and TNF-α [36]. 
Han et al. demonstrated higher circulating CTRP 1 levels in 
prediabetes/type 2 diabetes group than in control one. These 
levels are positively correlated with HOMAR-IR, fasting blood 
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glucose concentration, age and BMI. T2DM and GDM have 
similar pathogenesis, so circulating the test for CTRP1 might 
be useful as diagnostic test for GDM [37]. However, the limited 
data addressing the use of CTRP 1 as a diagnostic test in GDM 
are available and further studies are necessary. 
CONCLUSIONS
Gestational diabetes mellitus affects a significant num-
ber of women during pregnancy. GDM is characterized by 
altered concentrations of different adipokines. The exact 
significance of adipokines in the pathogenesis of GDM 
remains unclear. Several adipokines have been analysed 
throughout gestation and their levels have been assessed 
in healthy and complicated pregnancies but the final set-
tlement over their usefulness as predictive biomarkers of 
abnormal glucose metabolism is still to be elucidated. 
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